[ROCHE PHARMACEUTICALS GRANTRISIN SULFISOXAZOLE ANTIBIOTIC PROMOTIONAL FILM]

Year Published: 1970s

Creator: hoffman-la-roche

Description: This 1970s industrial commercial promotes Hoffman-La Roche's Gantrisin sulfisoxazole, which is a sulfonamide (sulfa) antibiotic used to treat various bacterial infections including UTI. Sulfisoxazole is used to treat or prevent many different types of infections caused by bacteria, such as bladder infections, ear infections, or meningitis. The brand name Gantrisin is discontinued, but generic versions may be available. Note: Gantrisin (sulfisoxazole, a single-entity sulfonamide drug manufactured by Hoffmann-La Roche) was a prominent antibiotic, particularly for urinary tract infections, in the mid-to-late 20th century. Larotid is a former brand name for the generic prescription antibiotic medication amoxicillin. It is a penicillin-like antibiotic used to treat various bacterial infections. 0:00 Introduction to Change. The narrator discusses the constant nature of change in society, families, and specifically in the field of clinical medicine, noting how pathogens evolve to develop resistance. 0:25 The Host Environment. The commercial explains that the effectiveness of drugs can change as the host environment fluctuates due to inflammation, tissue damage, and impaired defenses during bacterial cystitis. 0:39 Introduction to Gantrisin. Amidst these changes, the sulfonamide Gantrisin (sulfisoxazole Roche) is introduced as a drug that maintains continuing efficacy for treating urinary tract infections (UTIs). 0:51 Clinical Study Results. A cooperative study of 24 physicians involving 289 patients with uncomplicated UTIs is cited. The study tested Gantrisin against various organisms, including E. coli and Klebsiella. 1:10 Efficacy Data. Using different standards of measurement, the drug showed high success rates: 93 percent achieved clear culture by standard criteria, and even by the strictest standard of sterile urine, 90.6 percent showed clear culture. 1:32 Safety and Side Effects. Side effects are described as few and non-serious. However, Gantrisin is contraindicated for pregnant women, nursing mothers, and infants under two months old. 1:40 Therapy Requirements. During treatment, physicians are advised to ensure patients maintain adequate fluid intake and undergo frequent CBCs and urinalysis with microscopic examination. 1:48 Conclusion. The ad concludes by framing Gantrisin as a reliable solution in the challenging world of anti-infective medicine, offering a favorable balance of efficacy, safety, and economy for acute cystitis. 2:04 Product Information. A final note directs viewers to the full product information found in the booklet attached to the NCME video cassette container.

Complete Record: This 1970s industrial commercial promotes Hoffman-La Roche's Gantrisin sulfisoxazole, which is a sulfonamide (sulfa) antibiotic used to treat various bacterial infections including UTI. Sulfisoxazole is used to treat or prevent many different types of infections caused by bacteria, such as bladder infections, ear infections, or meningitis. The brand name Gantrisin is discontinued, but generic versions may be available. Note: Gantrisin (sulfisoxazole, a single-entity sulfonamide drug manufactured by Hoffmann-La Roche) was a prominent antibiotic, particularly for urinary tract infections, in the mid-to-late 20th century. Larotid is a former brand name for the generic prescription antibiotic medication amoxicillin. It is a penicillin-like antibiotic used to treat various bacterial infections. 0:00 Introduction to Change. The narrator discusses the constant nature of change in society, families, and specifically in the field of clinical medicine, noting how pathogens evolve to develop resistance. 0:25 The Host Environment. The commercial explains that the effectiveness of drugs can change as the host environment fluctuates due to inflammation, tissue damage, and impaired defenses during bacterial cystitis. 0:39 Introduction to Gantrisin. Amidst these changes, the sulfonamide Gantrisin (sulfisoxazole Roche) is introduced as a drug that maintains continuing efficacy for treating urinary tract infections (UTIs). 0:51 Clinical Study Results. A cooperative study of 24 physicians involving 289 patients with uncomplicated UTIs is cited. The study tested Gantrisin against various organisms, including E. coli and Klebsiella. 1:10 Efficacy Data. Using different standards of measurement, the drug showed high success rates: 93 percent achieved clear culture by standard criteria, and even by the strictest standard of sterile urine, 90.6 percent showed clear culture. 1:32 Safety and Side Effects. Side effects are described as few and non-serious. However, Gantrisin is contraindicated for pregnant women, nursing mothers, and infants under two months old. 1:40 Therapy Requirements. During treatment, physicians are advised to ensure patients maintain adequate fluid intake and undergo frequent CBCs and urinalysis with microscopic examination. 1:48 Conclusion. The ad concludes by framing Gantrisin as a reliable solution in the challenging world of anti-infective medicine, offering a favorable balance of efficacy, safety, and economy for acute cystitis. 2:04 Product Information. A final note directs viewers to the full product information found in the booklet attached to the NCME video cassette container.